[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-stream-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-stream-infection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100626105","phase-2-safety-pharmacokinetics-and-efficacy-of-bv100-plus-low-dose-polymyxin-b-plus-ceftazidimeavibactam-or-plus-cefiderocol-in-patients-with-pulmonary-and-extrapulmonary-infections-due-to-carbapenem-resistant-acinetobacter-baumannii-calcoaceticus-complex-100626105",false,"NCT07431307","Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime\u002FAvibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","A Two-part Phase IIb Randomized, Multicenter, Open-label Comparative Study to Firstly Evaluate the Safety and Efficacy Trial of BV100 in Combination With Low Dose Polymyxin B Plus Ceftazidime\u002FAvibactam, or Plus Cefiderocol Versus Best Available Therapy in Patients With Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia and Bloodstream Infection, Suspected or Confirmed to be Due to Carbapenem-resistant Acinetobacter Baumannii Calcoaceticus Complex (CRABC), and Secondly to Evaluate the Pharmacokinetics of BV100 in Combination With Low Dose Polymyxin B Plus Cefideroc","RIV- CARE","Inclusion Criteria:\n\n1. Provide written informed consent prior to any study-related procedures not part of normal medical care. Surrogate consent\u002Fuse of a legally authorized representative may be provided if permitted by local country and institution-specific guidelines\n2. Male subjects or female subjects ≥ 18 and ≤ 82 years of age at the time of signing informed consent.\n3. A known or highly suspected infection caused by CRABC (VABP, HABP, or BSI of non-urinary tract origin) as either a single pathogen or member of a polymicrobial infection\n4. Diagnosed with HABP, VABP or BSI\n5. Acute Physiology and Chronic Health Evaluation (APACHE II) score ≤ 30, within 24 hours prior to randomization.\n\n   Part B specific inclusion criteria\n6. Confirmed CRABC ventriculitis or meningitis based on evidence from CSF culture collected within 72 hours prior to enrollment (as per standard of care).\n7. Functioning EVD that can be used for safe and timely CSF sampling.\n8. No contraindications to CSF sampling via EVD in the volumes required by the protocol\n\nMain Exclusion Criteria:\n\n1\\. Urinary tract infection as source of A. baumannii BSI2. Known or suspected community acquired bacterial pneumonia or viral (including SARS-CoV-2), pneumonia within the last 7 days 3. Known or suspected viral pneumonia within the last 7 days before screening e.g. positive for SARS-CoV-2 or influenza.\n\n4\\. Known fungal or parasitic pneumonia. 5. Patients classified under futility of care, as determined by the medical team, indicating a lack of potential for benefit from intervention or patients who are permanent residents of long-term care facilities and have been assessed as receiving palliative or comfort-focused care.\n\n6\\. Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure ≥ 65 mmHg (calculate mean arterial pressure = diastolic pressure plus 1\u002F3 (systolic pressure minus diastolic pressure)) with patients requiring escalating vasopressor support to maintain adequate arterial pressure in conjunction with rising lactate.7. Known or suspected allergies to polymyxins, rifabutin, ceftazidime\u002Favibactam, cefiderocol, or their excipients.\n\n8\\. Inability to insert a central catheter or a peripherally inserted central catheter (PICC).11. Acute graft versus host disease Grade ≥ 3.\n\n12\\. Expected survival \\\u003C 72 hours or a Do Not Resuscitate Order. 13. Burns \\> 40% of total body surface area. 14. Presence of neutropenia (absolute neutrophil count \\\u003C 1500\u002Fmm3) obtained from a local laboratory at Screening, or anticipated neutropenia with absolute neutrophil count \\\u003C 1500 cells\u002Fmm3.\n\n15\\. Severe renal disease defined as an estimated glomerular filtration rate (eGFR) as per Modification of Diet in Renal Disease (MDRD) formula (MDRD eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2, or requirement for peritoneal dialysis, hemodialysis, hemofiltration, or a urine output \\\u003C 20 mL\u002Fhour over a 24 hour period.","ALL","18 Years","82 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This Phase IIb study aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime\u002Favibactam or cefiderocol in patients with suspected or confirmed CRABC infections. The study is divided into two parts (Part A and Part B), recruiting in parallel. Approximately 10 subjects will be recruited in Part B, with enrollment ending once Part A enrollment is complete (at least 30 patients randomized to all of the three groups). Eligible patients, who have given informed consent, will be enrolled, and pre-treatment microbiology samples submitted to a local laboratory.",[28,29,30,31,32],"Ventilator Associated Bacterial Pneumonia (VABP)","Hospital Acquired Bacterial Pneumonia (HABP)","Blood Stream Infection","Meningitis, Bacterial","Ventriculitis, Infectious",[34,35,36,37,38,39],"VABP","BV100","HABP","BSI","CNS infection","BioVersys","NOT_YET_RECRUITING","2026-02-23",{"date":43,"type":44},"2026-02-24","ACTUAL",{"date":46,"type":22},"2026-07",{"date":48,"type":22},"2028-07",{"name":50,"class":51},"BioVersys AG","INDUSTRY",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100580153","antimicrobial-combination-therapy-for-treatment-of-enterococcus-faecalis-bacteremia-100580153","NCT06833593","Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia","Efficacy of Optimized Antimicrobial Combination Therapy for Treatment of Enterococcus Faecalis Bacteremia and Identification of Intestinal Microbiota Signature","MicroEFfAECT","Inclusion Criteria:\n\n* Adult (≥18 years)\n* Monomicrobial EF-BSI\n* Receipt of ≥ 5 days of at least one in vitro active drug (ampicillin, amoxicillin\u002Fclavulanate, ampicillin\u002Fsulbactam, piperacillin, vancomycin, teicoplanin, daptomycin and linezolid) with or without a synergistic drug (ceftriaxone, gentamycin, streptomycin), at common suggested dosages for EF-BSI in empirical or definitive therapy\n* Written informed consent\n\nExclusion Criteria:\n\n* Short term (within 3 days from BSI) mortality\n* Other concomitant infection",{"count":61,"type":22},510,"OBSERVATIONAL","Prospective, multicenter, national, observational pharmacological study on the evaluation of efficacy of appropriate monotherapy vs combination treatment for non-complicated Enterococcus faecalis (EF) bloodstream infection (BSI) and identification of gut microbiota fingerprint of patients with EF-BSI correlated to antimicrobial treatment and clinical outcome",[65,30,66],"Enterococcus Faecalis Infection","Gut Microbiomes",[68,69,70,71],"Enterococcus faecalis bloodstream infection","Human tissue analysis in vitro","Gut microbiota analysis","Enterococcus faecalis genomic analysis","RECRUITING","2025-11-26",{"date":75,"type":44},"2025-12-03",{"date":77,"type":44},"2021-02-06",{"date":79,"type":22},"2026-09-26",{"name":81,"class":82},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",4,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100586722","examination-of-the-large-intestine-with-camera-capsule-in-patients-with-blood-stream-infection-with-gut-associated-bacteria-100586722","NCT06919068","Examination of the Large Intestine With Camera Capsule in Patients With Blood Stream Infection With Gut-associated Bacteria","Colonic Capsule Endoscopy for Screening of Neoplasms in Patients With Anaerobic Bacteremia","AB-care","Inclusion Criteria:\n\n* Older than 18 years\n* Blood culture with growth of one or more of the following bacterial genera Bacteroides, Clostridium, Filifactor, Fusobacterium, Gemella, Granulicatella, Parvimonas, Peptostreptococcus, Prevotella, Solobacterium, Peptoniphilus, Ruminococcus, Finegoldia and Streptococcus.\n* Able to provide oral and written informed consent\n* Able to read and speak Danish\n\nExclusion Criteria:\n\n* Prior colorectal cancer diagnosis\n* History of stenosis of the gastrointestinal tract\n* Previous treatment of inflammatory bowel disease\n* Previous major surgery of the gastrointesinal tract (e.g. gastric bypass)\n* Colostomy\n* Pacemaker\u002FICD\n* Pregnancy or breastfeeding\n* Allergies to the bowel preparation regimen\n* Severe kidney disease\n* Focus of infection in skin and soft tissue or outside the truncus (e.g. decubitus, diabetic foot ulcer)\n* Tumor in the colon or rectum at diagnostic imaging\n* Transfer to other hospital outside the region",true,{"count":94,"type":22},100,"The goal of this observational study is to diagnose colorectal cancer or precancerous tumors in participants over the age of 18 hospitalized with blood stream infection with anaerobic gut-associated bacteria. The main question it aims to answer is:\n\n• How prevalent is cancer and precancerous tumors in the large intestines and rectum in patients with anaerobic bacteremia? Participants will be offered an examination using colon capsule endoscopy 4-8 weeks after discharge.",[97,98,30,99,100],"Colorectal Cancer (CRC)","Colorectal Cancer and Pre-cancer Polyps","Anaerobic Infection","Bacteriaemia",[102,103,104,105,106,107,108],"Colorectal Cancer","Anaerobic bacteria","Bacteria, anaerobic","Cancer, colorectal","Bacteremia","Blood stream infection","Colon capsule endoscopy","2025-11-17",{"date":111,"type":44},"2025-11-18",{"date":113,"type":44},"2025-04-23",{"date":115,"type":22},"2027-12",{"name":117,"class":82},"Odense University Hospital",1]